Melane Sampson, Author at BioTuesdays

Developments

Santhera inks exclusive distribution deal with Clinigen for AGAMREE in DMD

Santhera Pharmaceuticals (SIX:SANN) and closely held Clinigen Group have announced the signing of a supply and distribution agreement that will make AGAMREE accessible to patients with Duchene muscular dystrophy (DMD)...

January 6, 2025

Developments

Clearmind granted patent for binge behavior treatment in Macau

Clearmind Medicine (NASDAQ:CMND; FSE:CWY0) has announced that its proprietary MEAI-based binge behavior regulator program has received patent approval from the Macau International Intellectual Property Office, a special...

January 3, 2025

Developments

Eton acquires rare disease product Galzin

Eton Pharmaceuticals (NASDAQ:ETON) has announced the acquisition of Galzin, a rare disease product used in the treatment of Wilson disease. The company reports that Galzin, an FDA-approved zinc acetate, is utilized as a...

January 3, 2025

Developments

Japan approves SIGA’s antiviral for orthopoxvirus

SIGA Technologies (NASDAQ:SIGA) has announced that its product, TEPOXX, an antiviral therapy targeting orthopoxviruses, has received approval from Japan’s Pharmaceuticals and Medical Devices Agency and the Japan...

January 3, 2025

Executive Moves

Grown Rogue announces Andrew Marchington as CFO and corporate secretary

Grown Rogue (CSE:GRIN; OTC:GRUSF) has appointed Andrew Marchington as its chief financial officer (CFO) and corporate secretary, succeeding Ryan Kee effective January 1, 2025. Previously serving as senior vice president...

January 2, 2025

Executive Moves

Avalo names Jennifer Riley as CSO

Avalo Therapeutics (NASDAQ: AVTX) has announced the appointment of Jennifer Riley as chief strategy officer (CSO), a newly created role effective January 1, 2025. Ms. Riley will oversee corporate strategy, as well as...

January 2, 2025

Developments

Oruka initiates dosing of first patient in Phase 1 trial of ORKA-001

Oruka Therapeutics (NASDAQ:ORKA) has announced the initiation of dosing of in its Phase 1 clinical trial of ORKA-001, a subcutaneously administered, half-life extended monoclonal antibody targeting IL-23p19. Inhibitors...

December 20, 2024

Executive Moves

Adicet appoints Julie Maltzman as CMO

Adicet Bio (NASDAQ:ACET) has appointed Julie Maltzman, MD, as chief medical officer (CMO), effective January 13, 2025. Adicet reports that Dr. Maltzman succeeds Dr. Francesco Galimi, who has completed his tenure with...

December 18, 2024

Developments

Silo initiates PK and tolerability study for non-opioid extended-release pain therapeutic

Silo Pharma (NASDAQ:SILO) has announced the initiation of a preclinical pharmacokinetic (PK) and tolerability study, in partnership with AmplifyBio, to assess Silo’s dissolvable, ketamine-based injectable implant, SP-26...

December 18, 2024

Feature

GRIN targeting rare pediatric neurological disorders with precision therapies

Closely-held GRIN Therapeutics, a Neurvati Neuroscience company, is advancing promising research and development of precision therapeutics for neurodevelopmental disorders, predominately affecting children from infancy...

December 17, 2024

Author - Melane Sampson

Santhera inks exclusive distribution deal with Clinigen for AGAMREE in DMD

Clearmind granted patent for binge behavior treatment in Macau

Eton acquires rare disease product Galzin

Japan approves SIGA’s antiviral for orthopoxvirus

Grown Rogue announces Andrew Marchington as CFO and corporate secretary

Avalo names Jennifer Riley as CSO

Oruka initiates dosing of first patient in Phase 1 trial of ORKA-001

Adicet appoints Julie Maltzman as CMO

Silo initiates PK and tolerability study for non-opioid extended-release pain therapeutic

GRIN targeting rare pediatric neurological disorders with precision therapies

Subscribe